![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reliance Gen. | LSE:GMX | London | Ordinary Share | GB00B1MM9925 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.55 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:1963U GeneMedix PLC 14 January 2004 14th January 2004 GENEMEDIX PLC GeneMedix appoints US Investment Bankers GeneMedix plc ("GeneMedix" or "the Company"), the UK biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, today announces that it has appointed the New York based Investment Bankers, Global Markets Capital Group, LLC, to act as its strategic and corporate advisors in the US. GeneMedix is involved in the development and manufacture of generic and second-generation versions of therapeutic proteins using recombinant DNA technology and novel cell culture. Global Markets Capital Group will assist GeneMedix to develop its corporate activities and target strategic US merger and acquisition initiatives. This will be supported by a programme of accessing the US capital markets with a view to increasing shareholder value, broadening GeneMedix's shareholder base and improving the Company's financial position. Mr Mark Saunders, President of Global Markets Capital Group, stated: "With over a quarter of all new drugs approved since 2000 classed as biopharmaceuticals,approximately 500 candidate biopharmaceuticals currently undergoing clinical evaluation, and pipelines in pharmaceutical companies appearing to be under increasing pressure, we expect to see sustained and strong growth within the biogenerics sector. We believe that GeneMedix is well positioned to take advantage of these opportunities." Commenting on the appointment, Paul Edwards, Chief Executive Officer of GeneMedix plc said: "We have selected Global Markets Capital due to their sector expertise and US contacts. The recent debate in the USA regarding the route for licensing biogenerics has heightened the profile of the sector and we therefore feel the time is right for GeneMedix to look at strategic opportunities in the USA and to position itself to access this significant market as it opens up." Editors' Note About GeneMedix GeneMedix is a UK based biopharmaceutical company focused on the development of biogenerics, or generic versions of currently marketed biopharmaceutical therapeutics, including erythropoietin (EPO) for the treatment of anaemia, recombinant insulin for the treatment of diabetes, and interferon alfa for the treatment of hepatitis C and hepatitis B. About Global Markets Capital Group Global Markets Capital Group, LLC is an independent investment banking firm providing innovative strategic advisory services and mergers and acquisitions expertise globally to public and private companies. Through its advisory roles and its network of global companies active in Europe, Asia, Australia and the US, the firm has assisted numerous international life sciences and emerging technology companies in achieving their strategic goals. ENQUIRIES: GeneMedix plc Tel: 01638 663 320 Paul Edwards, Chief Executive Officer Global Markets Capital Group, LLC Tel: 01 212 808 9700 Mark Saunders, President Bankside Consultants Tel: 0207 444 4140 Michael Padley/Susan Scott Further copies are available from the Group's head office - Rosalind Franklin House, Fordham Road, Newmarket, Suffolk, CB8 7XN This information is provided by RNS The company news service from the London Stock Exchange END MSCGUUPUGUPCGMW
1 Year Reliance Genemedix Chart |
1 Month Reliance Genemedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions